COLLETTE ODIBO: Open Payments
NPI 1255661294 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,242 in 57 payments from 10 companies in 2025. Trend: 2023 $604 · 2024 $1,098 · 2025 $1,242
Food & beverage: $1,242
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 16 | $244 |
| Vanda Pharmaceuticals Inc. | 7 | $212 |
| ABBVIE INC. | 10 | $181 |
| E.R. Squibb & Sons, L.L.C. | 7 | $170 |
| Lundbeck LLC | 6 | $132 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $89 |
| Alkermes, Inc. | 3 | $74 |
| Neurocrine BioSciences, Inc. | 3 | $62 |
| Janssen Pharmaceuticals, Inc | 1 | $42 |
| HARMONY BIOSCIENCES LLC | 1 | $36 |
Products named: ABILIFY ASIMTUFII, REXULTI, VRAYLAR, COBENFY, FANAPT, CAPLYTA, HETLIOZ, INGREZZA.
Industry payments across DC — which companies pay providers there.
